Immunocore announces key appointments to management and Board
February 16, 2021 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore announces key appointments to management and Board Ralph Torbay appointed Head of Commercial to spearhead the launch of tebentafusp Dr. Roy S. Herbst appointed as a...
Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0 Million Concurrent Private Placement
February 09, 2021 16:05 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297.1 Million Initial Public Offering, Full Exercise of Option to Purchase Additional ADSs and $15.0...
Immunocore Announces Pricing of Upsized Initial Public Offering
February 04, 2021 22:07 ET
|
Immunocore Limited
PRESS RELEASE Immunocore Announces Pricing of Upsized Initial Public Offering OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US – 4 February 2021 – Immunocore Holdings plc...
Immunocore announces closing of $75.0 Million Series C round
January 11, 2021 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore announces closing of $75.0 Million Series C round Funding follows positive Phase 3 trial interim analysis data for tebentafusp in patients with metastatic uveal melanoma ...
Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020
December 03, 2020 06:01 ET
|
Immunocore Limited
PRESS RELEASE Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 3...
Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
November 23, 2020 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal...
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
August 27, 2020 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B
August 27, 2020 02:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B New preclinical...
Immunocore announces dosing of first patient with fourth ImmTAC®
May 26, 2020 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore announces dosing of first patient with fourth ImmTAC® IMC-F106C studied for the treatment of advanced cancers that express PRAME (OXFORDSHIRE, England & CONSHOHOCKEN,...
Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy
May 06, 2020 07:00 ET
|
Immunocore Limited
PRESS RELEASE Immunocore appoints Brian Di Donato as Chief Financial Officer and Head of Strategy (OXFORD, England & CONSHOHOCKEN, Pa. & ROCKVILLE, Md., 6 May 2020) Immunocore, a...